Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma
To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995...
Saved in:
| Published in | Cancer management and research Vol. 11; pp. 5187 - 5195 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Dove Medical Press Limited
01.06.2019
Dove Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC).
Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI).
On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7
TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279,
<0.001) and 0.425 (95% CI, 0.044-0.806,
=0.03), respectively.
Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. |
|---|---|
| AbstractList | Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, [gamma]-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7th TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, P<0.001) and 0.425 (95% CI, 0.044-0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. Keywords: combined hepatocellular cholangiocarcinoma, recurrence prediction, prognosis, liver resection Meng-Xin Tian,1,2,* Liu-Ping Luo,3,4,* Wei-Ren Liu,1,2,* Wei Deng,5 Jia-Cheng Yin,1,2 Lei Jin,1,2 Xi-Fei Jiang,1,2 Yu-Fu Zhou,1,2 Wei-Feng Qu,1,2 Zheng Tang,1,2 Han Wang,1,2 Chen-Yang Tao,1,2 Yuan Fang,1,2 Shuang-Jian Qiu,1,2 Jian Zhou,1-2,6 Jing-Feng Liu,3,4 Jia Fan,1-2,6 Ying-Hong Shi1,21Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, People's Republic of China; 3Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China; 4The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China; 5Department of Health Statistics and Social Medicine, Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai, People's Republic of China; 6Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China*These authors contributed equally to this work Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC).Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI).Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7th, TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, P<0.001) and 0.425 (95% CI, 0.044-0.806, P=0.03), respectively.Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies.Keywords: combined hepatocellular cholangiocarcinoma, recurrence prediction, prognosis, liver resection Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7th TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, P<0.001) and 0.425 (95% CI, 0.044-0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies.Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7th TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, P<0.001) and 0.425 (95% CI, 0.044-0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7 th TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090–0.279, P <0.001) and 0.425 (95% CI, 0.044–0.806, P =0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7 TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, <0.001) and 0.425 (95% CI, 0.044-0.806, =0.03), respectively. Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies. |
| Audience | Academic |
| Author | Zhou, Jian Jiang, Xi-Fei Zhou, Yu-Fu Fan, Jia Liu, Wei-Ren Tang, Zheng Yin, Jia-Cheng Tao, Chen-Yang Qu, Wei-Feng Qiu, Shuang-Jian Liu, Jing-Feng Shi, Ying-Hong Fang, Yuan Jin, Lei Tian, Meng-Xin Luo, Liu-Ping Deng, Wei Wang, Han |
| Author_xml | – sequence: 1 givenname: Meng-Xin orcidid: 0000-0002-5315-1780 surname: Tian fullname: Tian, Meng-Xin – sequence: 2 givenname: Liu-Ping surname: Luo fullname: Luo, Liu-Ping – sequence: 3 givenname: Wei-Ren surname: Liu fullname: Liu, Wei-Ren – sequence: 4 givenname: Wei surname: Deng fullname: Deng, Wei – sequence: 5 givenname: Jia-Cheng surname: Yin fullname: Yin, Jia-Cheng – sequence: 6 givenname: Lei surname: Jin fullname: Jin, Lei – sequence: 7 givenname: Xi-Fei surname: Jiang fullname: Jiang, Xi-Fei – sequence: 8 givenname: Yu-Fu surname: Zhou fullname: Zhou, Yu-Fu – sequence: 9 givenname: Wei-Feng surname: Qu fullname: Qu, Wei-Feng – sequence: 10 givenname: Zheng surname: Tang fullname: Tang, Zheng – sequence: 11 givenname: Han surname: Wang fullname: Wang, Han – sequence: 12 givenname: Chen-Yang surname: Tao fullname: Tao, Chen-Yang – sequence: 13 givenname: Yuan surname: Fang fullname: Fang, Yuan – sequence: 14 givenname: Shuang-Jian surname: Qiu fullname: Qiu, Shuang-Jian – sequence: 15 givenname: Jian surname: Zhou fullname: Zhou, Jian – sequence: 16 givenname: Jing-Feng surname: Liu fullname: Liu, Jing-Feng – sequence: 17 givenname: Jia surname: Fan fullname: Fan, Jia – sequence: 18 givenname: Ying-Hong surname: Shi fullname: Shi, Ying-Hong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31239773$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkstrGzEQxpeS0jzaW89loZccalevlVaXgnEfCaQU-jgL7Wh2rbArudq1oYf-75VjJ8Ql6KDR6JsfM8N3XpyEGLAoXlMyZ1So98uvi-_zH1RXWopnxRmlSs8oZ-zkUXxanI_jLSFSUy5eFKecMq6V4mfF34-4xT6uBwxTaYMrt7b3zk4-hjK2pS3XKXYhjpOHcoSYMCfQeZh86MqEsEkJA2DpQ36NCBO6EuLQ-JCDFa7tFAH7ftPbVMIq9jZ0PoJN4EMc7MvieWv7EV8d7ovi1-dPP5dXs5tvX66Xi5sZVDWfZo1sRCU5trxSUtSt09Qx5kBRTamgqGtX1bUQBFzTMqsaSSuhkVUaG4kA_KK43nNdtLdmnfxg0x8TrTd3iZg6Y1MesUcDDRKttBKOE2EZtU3DLJMEJCgtSZNZH_as9aYZ0EFeXLL9EfT4J_iV6eLWyKqSQlYZcHkApPh7g-NkBj_ulmQDxs1oGKtIHoAokqVv99LO5tZ8aGMmwk5uFpIowRmvWVbNn1Dl43DwkN3S-pw_KnjzeISH3u9tkQVsL4AUxzFha8BPd6bIZN8bSszOe2bnPXPwXi5691_RPfdJ-T9l3dwj |
| CitedBy_id | crossref_primary_10_1159_000507320 crossref_primary_10_1186_s12957_020_02099_w crossref_primary_10_1007_s00464_022_09579_y crossref_primary_10_1007_s11547_023_01726_2 crossref_primary_10_1186_s12957_022_02536_y crossref_primary_10_1002_cam4_5328 crossref_primary_10_1016_j_hpb_2020_07_007 crossref_primary_10_4254_wjh_v16_i5_766 crossref_primary_10_1016_j_clinre_2021_101695 crossref_primary_10_3390_cancers12040794 crossref_primary_10_1002_jum_15869 crossref_primary_10_18632_aging_103577 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 Dove Medical Press Limited 2019 Tian et al. 2019 Tian et al. |
| Copyright_xml | – notice: COPYRIGHT 2019 Dove Medical Press Limited – notice: 2019 Tian et al. 2019 Tian et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.2147/CMAR.S195964 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Tian et al |
| EISSN | 1179-1322 |
| EndPage | 5195 |
| ExternalDocumentID | oai_doaj_org_article_cbe097974d304a21abb2a260c6c7960b PMC6556465 A607432382 31239773 10_2147_CMAR_S195964 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 0YH 29B 2WC 53G 5VS 7X7 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IPNFZ ITC KQ8 M2O M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV NPM PMFND 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c583t-b6b4563ef357648fd91d22dc7191141e98d588440cdbf2a7b61549e259eb6ecc3 |
| IEDL.DBID | M48 |
| ISSN | 1179-1322 |
| IngestDate | Wed Aug 27 01:00:46 EDT 2025 Thu Aug 21 18:21:17 EDT 2025 Fri Jul 11 11:15:05 EDT 2025 Tue Jun 17 21:59:12 EDT 2025 Tue Jun 10 20:59:37 EDT 2025 Thu Jan 02 23:02:31 EST 2025 Thu Apr 24 22:51:45 EDT 2025 Tue Jul 01 03:18:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | liver resection recurrence prediction prognosis combined hepatocellular cholangiocarcinoma |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-b6b4563ef357648fd91d22dc7191141e98d588440cdbf2a7b61549e259eb6ecc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
| ORCID | 0000-0002-5315-1780 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/CMAR.S195964 |
| PMID | 31239773 |
| PQID | 2250615070 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cbe097974d304a21abb2a260c6c7960b pubmedcentral_primary_oai_pubmedcentral_nih_gov_6556465 proquest_miscellaneous_2250615070 gale_infotracmisc_A607432382 gale_infotracacademiconefile_A607432382 pubmed_primary_31239773 crossref_citationtrail_10_2147_CMAR_S195964 crossref_primary_10_2147_CMAR_S195964 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06 |
| PublicationDateYYYYMMDD | 2019-06-01 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand |
| PublicationTitle | Cancer management and research |
| PublicationTitleAlternate | Cancer Manag Res |
| PublicationYear | 2019 |
| Publisher | Dove Medical Press Limited Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
| SSID | ssj0069134 |
| Score | 2.2201176 |
| Snippet | To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular... Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular... Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular... Meng-Xin Tian,1,2,* Liu-Ping Luo,3,4,* Wei-Ren Liu,1,2,* Wei Deng,5 Jia-Cheng Yin,1,2 Lei Jin,1,2 Xi-Fei Jiang,1,2 Yu-Fu Zhou,1,2 Wei-Feng Qu,1,2 Zheng... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 5187 |
| SubjectTerms | Combined hepatocellular-cholangiocarcinoma Liver Liver cancer liver resection Medical research Medicine, Experimental Metastasis Original Research prediction Prognosis recurrence Risk factors Tumor staging |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFH5COyAuCBg_wgYyEogDCmsSx2mPZdo0IZUDMGk3y7_CKjFnarsj_zvfi9OqEUJcOFSqYjd1_J79vi9-_kz0tnBF4PWW3Adpc-lam5vWmtyGgpf5anyYKC6-qItL-fmqvto76otzwpI8cOq4E2dxrwao14N4m7Iw1pYGINwp1wB9W559EfO2ZCrNwWq7ngx3y5lvpZR3PpPnxN2Y1cc1a6ooOQpGvWb_nzPzXmgap03uxaHzR_RwAJBinhr-mO6F-ITuL4Yl8kP6tZcGJEz0Aq60TAcnia4VRnBGVuxYnlmsWcMSF_jHnP4sVvz2vd__J5ZR8M4kB0Qq4JUg0PhyjeC16fhlP2evip4Yxx9LxMMV_r27MU_p8vzs--lFPpyxkLt6Wm1yqywgVBXaCsRDTls_K3xZeteAxxWyCLOp562scuK8bUvTWMWabgGkKVgF81fP6CB2MbwgUQHreN-4AAgk24pvbKeFaaSdsNZByOjDtrO1GwTI-RyMnxpEhE2jTxfzr_pbMk1G73a1b5Pwxl_qfWK77eqwXHZ_AU6kByfS_3KijN6z1TUPajTJmWFvAh6M5bH0XDHSAropMzoe1cRgdKPiN1u_0VzEGWwxdHdrjXmzF99vJhk9T360a3MF-AAcXmXUjDxs9FDjkri87rXAVV0rqeqX_6MXjugB4OAsJcId08FmdRdeAXJt7Ot-dP0GoPsq3g priority: 102 providerName: Directory of Open Access Journals |
| Title | Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31239773 https://www.proquest.com/docview/2250615070 https://pubmed.ncbi.nlm.nih.gov/PMC6556465 https://doaj.org/article/cbe097974d304a21abb2a260c6c7960b |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1La9tAEB7ygJBL6TtqU7OFlh6KUq-02rUPpTghaSg4lLQG35Z9KTGkUis70B763zujh7FIc7Ax2pUs7Xy7M6OZ_QbgDXc8ULwl9kHYWLjcxia3JraBU5gvww85itMLeT4TX-bZfAu6aqPtAC7_69pRPalZdXP0-9efTzjhP1IaMxfqw8l0cnn0jVhSpNiGXdRJimoZTMU6niC7-DLCLyb_q0mBv3P2PuyluJSjTZT29FRN53930d7QWv2Myg0VdfYQHrS2JZs0YHgEW6F4DHvTNnr-BP5uZAgxU3iGKFs0NZVYmTPDKFmrKIm5mS2J3hIP0MmUGc0qejFfbw1ki4LRpiWHxipDwKJvjT-uUa-tSooDUGIrqwe2uFqgqqzw38sf5inMzk6_n5zHbfmF2GWjdBVbadG6SkOeok8iRrkfc58k3il08bjgYTzytMtVDJ23eWKUlUT3FtCfClYiMtJnsFOURTgAlqIZ5L1yAa0jkad0YTviRgk7JBqEEMH7brC1a7nJqUTGjUYfhaSkSUq6lVIEb9e9fzacHPf0Oya5rfsQk3Z9oKyudDsxtbOIVYVelU-HwiTcWJsYdPKcdAq9OxvBO5K6JgTiLTnTblvAByPmLD2RZISh4ZNEcNjrifPU9Zpfd7jR1ETJbUUob5cal9Sal18NI3je4Gh9zx0cI1A9hPUeqt9SLK5rmnCZZVLI7MW913wJ-2j-jZvEt0PYWVW34RWaWCs7gG01VwPYPT69-Ho5qF9U4PfnOR_U8-ofy0MoSg |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+validation+of+a+prognostic+score+predicting+recurrence+in+resected+combined+hepatocellular+cholangiocarcinoma&rft.jtitle=Cancer+management+and+research&rft.au=Tian%2C+Meng-Xin&rft.au=Luo%2C+Liu-Ping&rft.au=Liu%2C+Wei-Ren&rft.au=Deng%2C+Wei&rft.date=2019-06-01&rft.issn=1179-1322&rft.eissn=1179-1322&rft.volume=11&rft.spage=5187&rft_id=info:doi/10.2147%2FCMAR.S195964&rft_id=info%3Apmid%2F31239773&rft.externalDocID=31239773 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1322&client=summon |